Biomarkers for kidney transplant rejection

Nature Reviews Nephrology

Volumn 10, Issue 4, 2014, Pages 215-225

  Lo, Denise J ^a   Kaplan, Bruce ^b   Kirk, Allan D ^a  

^a EMORY UNIVERSITY   (United States)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; BIOLOGICAL MARKER; CD134 ANTIGEN; CD3 ANTIGEN; CHEMOKINE RECEPTOR CXCR3; CREATININE; CXCL9 CHEMOKINE; FAS LIGAND; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANZYME B; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; HLA DRB1 ANTIGEN; MESSENGER RNA; MICRORNA; MICRORNA 10B; MICRORNA 142; MICRORNA 155; MICRORNA 210; MICRORNA 223; MONOCYTE CHEMOTACTIC PROTEIN 1; OX40 LIGAND; PERFORIN; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ANTIBODY TITER; AREA UNDER THE CURVE; CD4+ T LYMPHOCYTE; CLINICAL DECISION MAKING; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; CREATININE BLOOD LEVEL; DELAYED GRAFT FUNCTION; GLOMERULUS FILTRATION RATE; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MOLECULAR STABILITY; PATIENT MONITORING; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; REVIEW; SENSITIVITY AND SPECIFICITY;

BIOLOGICAL MARKERS; CHEMOKINE CXCL10; GRAFT REJECTION; GRAFT SURVIVAL; GRANZYMES; HUMANS; IMMUNOSUPPRESSION; KIDNEY TRANSPLANTATION; MEMBRANE PROTEINS; MICRORNAS; OX40 LIGAND; PORE FORMING CYTOTOXIC PROTEINS; PROGNOSIS; RNA, MESSENGER;

EID: 84897108187     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2013.281     Document Type: Review

References (83)

1. Kaneku, H. K. & Terasaki, P. I. Thirty year trend in kidney transplants: UCLA and UNOS Renal Transplant Registry. Clin. Transpl. 1-27 (2006
2. Biomarker definitions workgroup. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69, 89-95 (2001
3. Lachenbruch, P. A., Rosenberg, A. S., Bonvini, E., Cavaille-Coll, M. W. & Colvin, R. B. Biomarkers and surrogate endpoints in renal transplantation: Present status and considerations for clinical trial design. Am. J. Transplant. 4, 451-457 (2004
4. Singh, N. et al. Pretransplant donor-specific antibodies detected by single-antigen bead flow cytometry are associated with inferior kidney transplant outcomes. Transplantation 90, 1079-1084 (2010
5. Racusen, L. C. et al. The Banff 97 working classification of renal allograft pathology. Kidney Int. 55, 713-723 (1999
6. Solez, K. et al. Banff 07 classification of renal allograft pathology: Updates and future directions. Am. J. Transplant. 8, 753-760 (2008
7. Thaunat, O., Legendre, C., Morelon, E., Kreis, H. & Mamzer-Bruneel, M. F. To biopsy or not to biopsy Should we screen the histology of stable renal grafts Transplantation 84, 671-676 (2007
8. Kirk, A. D. et al. Clinically stable human renal allografts contain histological and RNA-based findings that correlate with deteriorating graft function. Transplantation 68, 1578-1582 (1999
9. Rush, D. N., Henry, S. F., Jeffery, J. R., Schroeder, T. J. & Gough, J. Histological findings in early routine biopsies of stable renal allograft recipients. Transplantation 57, 208-211 (1994
10. Rush, D. et al. Lack of benefit of early protocol biopsies in renal transplant patients receiving TAC and MMF: A randomized study. Am. J. Transplant. 7, 2538-2545 (2007
11. Mueller, T. F. & Mas, V. R. Microarray applications in nephrology with special focus on transplantation. J. Nephrol. 25, 589-602 (2012
12. Mas, V. R., Dumur, C. I., Scian, M. J., Gehrau, R. C. & Maluf, D. G. MicroRNAs as biomarkers in solid organ transplantation. Am. J. Transplant. 13, 11-19 (2013
13. Sigdel, T. K. & Sarwal, M. M. Recent advances in biomarker discovery in solid organ transplant by proteomics. Expert Rev. Proteomics 8, 705-715 (2011
14. Chattopadhyay, P. K. & Roederer, M. Cytometry: Todays technology and tomorrows horizons. Methods 57, 251-258 (2012
15. Augustine, J. J. & Hricik, D. E. T-cell immune monitoring by the ELISPOT assay for interferon . Clin. Chim. Acta 413, 1359-1363 (2012
16. Barry, M. & Bleackley, R. C. Cytotoxic T lymphocytes: All roads lead to death. Nat. Rev. Immunol. 2, 401-409 (2002
17. Cornell, L. D., Smith, R. N. & Colvin, R. B. Kidney transplantation: Mechanisms of rejection and acceptance. Annu. Rev. Pathol. 3, 189-220 (2008
18. Vasconcellos, L. M. et al. Cytotoxic lymphocyte gene expression in peripheral blood leukocytes correlates with rejecting renal allografts. Transplantation 66, 562-566 (1998
19. Gibson, I. W. et al. Peritubular capillaritis in renal allografts: Prevalence, scoring system, reproducibility and clinicopathological correlates. Am. J. Transplant. 8, 819-825 (2008
20. Marcussen, N., Olsen, T. S., Benediktsson, H., Racusen, L. & Solez, K. Reproducibility of the Banff classification of renal allograft pathology. Inter-and intraobserver variation. Transplantation 60, 1083-1089 (1995
21. Aquino-Dias, E. C. et al. Non-invasive diagnosis of acute rejection in kidney transplants with delayed graft function. Kidney Int. 73, 877-884 (2008
22. Netto, M. V. et al. Granzyme, B., Fas-ligand and perforin expression during acute cellular rejection episodes after kidney transplantation: Comparison between blood and renal aspirates. Transplant. Proc. 34, 476-478 (2002
23. Sabek, O., Dorak, M. T., Kotb, M., Gaber, A. O. & Gaber, L. Quantitative detection of T-cell activation markers by real-time PCR in renal transplant rejection and correlation with histopathologic evaluation. Transplantation 74, 701-707 (2002
24. Graziotto, R. et al. Perforin, granzyme B, and Fas ligand for molecular diagnosis of acute renal-allograft rejection: Analyses on serial biopsies suggest methodological issues. Transplantation 81, 1125-1132 (2006
25. Heidt, S. et al. Peripheral blood sampling for the detection of allograft rejection: Biomarker identification and validation. Transplantation 92, 1-9 (2011
26. Kirk, A. D., Bollinger, R. R. & Finn, O. J. Rapid, comprehensive analysis of human cytokine mRNA and its application to the study of acute renal allograft rejection. Hum. Immunol. 43, 113-128 (1995
27. Strehlau, J. et al. Quantitative detection of immune activation transcripts as a diagnostic tool in kidney transplantation. Proc. Natl Acad. Sci. USA 94, 695-700 (1997
28. Reeve, J. et al. Molecular diagnosis of T cell-mediated rejection in human kidney transplant biopsies. Am. J. Transplant. 13, 645-655 (2013
29. Famulski, K. S. et al. Kidney transplants with progressing chronic diseases express high levels of acute kidney injury transcripts. Am. J. Transplant. 13, 634-644 (2013
30. Sellares, J. et al. Molecular diagnosis of antibody-mediated rejection in human kidney transplants. Am. J. Transplant. 13, 971-983 (2013
31. Li, L. et al. A peripheral blood diagnostic test for acute rejection in renal transplantation. Am. J. Transplant. 12, 2710-2718 (2012
32. Keslar, K. S. et al. Multicenter evaluation of a standardized protocol for noninvasive gene expression profiling. Am. J. Transplant. 13, 1891-1897 (2013
33. Hartono, C., Muthukumar, T. & Suthanthiran, M. Noninvasive diagnosis of acute rejection of renal allografts. Curr. Opin. Organ Transplant. 15, 35-41 (2010
34. Li, B. et al. Noninvasive diagnosis of renal-allograft rejection by measurement of messenger RNA for perforin and granzyme B in urine. N. Engl. J. Med. 344, 947-954 (2001
35. Galante, N. Z. et al. Noninvasive immune monitoring assessed by flow cytometry and real time RT-PCR in urine of renal transplantation recipients. Transpl. Immunol. 16, 73-80 (2006
36. Muthukumar, T. et al. Serine proteinase inhibitor-9, an endogenous blocker of granzyme B/perforin lytic pathway, is hyperexpressed during acute rejection of renal allografts. Transplantation 75, 1565-1570 (2003
37. Yannaraki, M. et al. Urinary cytotoxic molecular markers for a noninvasive diagnosis in acute renal transplant rejection. Transpl. Int. 19, 759-768 (2006
38. Muthukumar, T. et al. Messenger RNA for FOXP3 in the urine of renal-allograft recipients. N. Engl. J. Med. 353, 2342-2351 (2005
39. Afaneh, C. et al. Urinary cell levels of mRNA for OX40, OX40L, PD-1, PD-L1, or PD-L2 and acute rejection of human renal allografts. Transplantation 90, 1381-1387 (2010
40. Suthanthiran, M. et al. Urinary-cell mRNA profile and acute cellular rejection in kidney allografts. N. Engl. J. Med. 369, 20-31 (2013
41. Manfro, R. C. et al. Noninvasive TIM-3 messenger RNA evaluation in renal transplant recipients with graft dysfunction. Transplantation 86, 1869-1874 (2008
42. Renesto, P. G., Ponciano, V. C., Cenedeze, M. A., Saraiva Camara, N. O. & Pacheco-Silva, A. High expression of TIM-3 mRNA in urinary cells from kidney transplant recipients with acute rejection. Am. J. Transplant. 7, 1661-1665 (2007
43. Luo, Y., Shi, B., Qian, Y., Bai, H. & Chang, J. Sequential monitoring of TIM-3 gene expression in peripheral blood for diagnostic and prognostic evaluation of acute rejection in renal graft recipients. Transplant. Proc. 43, 3669-3674 (2011
44. Lo, D. J. et al. Chemokines and their receptors in human renal allotransplantation. Transplantation 91, 70-77 (2011
45. el-Sawy, T., Fahmy, N. M. & Fairchild, R. L. Chemokines: Directing leukocyte infiltration into allografts. Curr. Opin. Immunol. 14, 562-568 (2002
46. Hu, H. et al. Elevation of CXCR3-binding chemokines in urine indicates acute renal-allograft dysfunction. Am. J. Transplant. 4, 432-437 (2004
47. Dufour, J. H. et al. IFN-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J. Immunol. 168, 3195-3204 (2002
48. Miura, M. et al. Monokine induced by IFN- is a dominant factor directing T cells into murine cardiac allografts during acute rejection. J. Immunol. 167, 3494-3504 (2001
49. Hu, H., Kwun, J., Aizenstein, B. D. & Knechtle, S. J. Noninvasive detection of acute and chronic injuries in human renal transplant by elevation of multiple cytokines/chemokines in urine. Transplantation 87, 1814-1820 (2009
50. Schaub, S. et al. Urinary CXCL9 and CXCL10 levels correlate with the extent of subclinical tubulitis. Am. J. Transplant. 9, 1347-1353 (2009
51. Jackson, J. A. et al. Urinary chemokines CXCL9 and CXCL10 are noninvasive markers of renal allograft rejection and BK viral infection. Am. J. Transplant. 11, 2228-2234 (2011
52. Hricik, D. E. et al. Multicenter validation of urinary CXCL9 as a risk-stratifying biomarker for kidney transplant injury. Am. J. Transplant. 13, 2634-2644 (2013
53. Ho, J. et al. Early urinary CCL2 is associated with the later development of interstitial fibrosis and tubular atrophy in renal allografts. Transplantation 90, 394-400 (2010
54. Ho, J. et al. Increased urinary CCL2:Cr ratio at 6 months is associated with late renal allograft loss. Transplantation 95, 595-602 (2013
55. Guo, H., Ingolia, N. T., Weissman, J. S. & Bartel, D. P. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 466, 835-840 (2010
56. Sui, W. et al. Microarray analysis of microRNA expression in acute rejection after renal transplantation. Transpl. Immunol. 19, 81-85 (2008
57. Anglicheau, D. et al. MicroRNA expression profiles predictive of human renal allograft status. Proc. Natl Acad. Sci. USA 106, 5330-5335 (2009
58. Lorenzen, J. M. et al. Urinary miR-210 as a mediator of acute T-cell mediated rejection in renal allograft recipients. Am. J. Transplant. 11, 2221-2227 (2011
59. Valujskikh, A. & Lakkis, F. G. In remembrance of things past: Memory T cells and transplant rejection. Immunol. Rev. 196, 65-74 (2003
60. Kirk, A. D., Ibrahim, M. A., Bollinger, R. R., Dawson, D. V. & Finn, O. J. Renal allograft-infiltrating lymphocytes. A prospective analysis of in vitro growth characteristics and clinical relevance. Transplantation 53, 329-338 (1992
61. Heeger, P. S. et al. Pretransplant frequency of donor-specific, IFN-producing lymphocytes is a manifestation of immunologic memory and correlates with the risk of posttransplant rejection episodes. J. Immunol. 163, 2267-2275 (1999
62. Kim, S. H. et al. Pretransplant donor-specific interferon- ELISPOT assay predicts acute rejection episodes in renal transplant recipients. Transplant. Proc. 39, 3057-3060 (2007
63. Nather, B. J. et al. Modified ELISPOT technique-highly significant inverse correlation of post-Tx donor-reactive IFN-producing cell frequencies with 6 and 12 months graft function in kidney transplant recipients. Transpl. Immunol. 16, 232-237 (2006
64. Nickel, P. et al. Enzyme-linked immunosorbent spot assay for donor-reactive interferon-producing cells identifies T-cell presensitization and correlates with graft function at 6 and 12 months in renal-transplant recipients. Transplantation 78, 1640-1646 (2004
65. Bestard, O. et al. Cross-validation of IFN- ELISPOT assay for measuring alloreactive memory/effector T cell responses in renal transplant recipients. Am. J. Transplant. 13, 1880-1890 (2013
66. Kirk, A. D. et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (Campath-1H). Transplantation 76, 120-129 (2003
67. Kowalski, R. J. et al. Assessing relative risks of infection and rejection: A meta-analysis using an immune function assay. Transplantation 82, 663-668 (2006
68. Egli, A., Humar, A. & Kumar, D. State-of-the-art monitoring of cytomegalovirus-specific cell-mediated immunity after organ transplant: A primer for the clinician. Clin. Infect. Dis. 55, 1678-1689 (2012
69. Ginevri, F. et al. Prospective monitoring of polyomavirus BK replication and impact of pre-emptive intervention in pediatric kidney recipients. Am. J. Transplant. 7, 2727-2735 (2007
70. Ritta, M. et al. Evaluation of Epstein-Barr virus-specific immunologic response in solid organ transplant recipients with an enzyme-linked ImmunoSpot assay. Transplant. Proc. 45, 2754-2757 (2013
71. Abate, D. et al. Comparison of cytomegalovirus (CMV) enzyme-linked immunosorbent spot and CMV QuantiFERON interferon-releasing assays in assessing risk of CMV infection in kidney transplant recipients. J. Clin. Microbiol. 51, 2501-2507 (2013
72. Walker, S. et al. Ex vivo monitoring of human cytomegalovirus-specific CD8+ T-cell responses using QuantiFERON-CMV. Transpl. Infect. Dis. 9, 165-170 (2007
73. Newell, K. A. et al. Identification of a B cell signature associated with renal transplant tolerance in humans. J. Clin. Invest. 120, 1836-1847 (2010
74. Sagoo, P. et al. Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans. J. Clin. Invest. 120, 1848-1861 (2010
75. Brouard, S. et al. Identification of a gene expression profile associated with operational tolerance among a selected group of stable kidney transplant patients. Transpl. Int. 24, 536-547 (2011
76. Patel, R. & Terasaki, P. I. Significance of the positive crossmatch test in kidney transplantation. N. Engl. J. Med. 280, 735-739 (1969
77. Gebel, H. M. & Bray, R. A. The evolution and clinical impact of human leukocyte antigen technology. Curr. Opin. Nephrol. Hypertens. 19, 598-602 (2010
78. Terasaki, P. I., Ozawa, M. & Castro, R. Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival. Am. J. Transplant. 7, 408-415 (2007
79. Wiebe, C. et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am. J. Transplant. 12, 1157-1167 (2012
80. Reed, E. F. et al. Comprehensive assessment and standardization of solid phase multiplex-bead arrays for the detection of antibodies to, HLA. Am. J. Transplant. 13, 1859-1870 (2013
81. Archdeacon, P. et al. Summary of FDA antibody-mediated rejection workshop. Am. J. Transplant. 11, 896-906 (2011
82. Kirk, A. D. Meteorology and tolerance. Am. J. Transplant. 6, 645-646 (2006
83. Morel, P. A., Taasan, S., Morel, B. F., Kirschner, D. E. & Flynn, J. L. New insights into mathematical modeling of the immune system. Immunol. Res. 36, 157-165 (2006